Kidner Travis, Dai Menghua, Adusumilli Prasad S, Fong Yuman
Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Surg Oncol Clin N Am. 2008 Apr;17(2):377-89, ix. doi: 10.1016/j.soc.2008.01.002.
Hepatocellular cancer (HCC) is the fifth-leading cause of cancer and the third-leading cause of cancer related deaths world-wide. Current treatment options are limited, as HCC has been shown to be a highly resistant type of cancer to most current treatment modalities. Novel approaches are being explored in the fields of gene therapy, viral oncolytics, radioembolization, and several new biologic therapies. This article summarizes these recent clinical findings and discusses what role they will have in the future treatment of HCC.
肝细胞癌（HCC）是全球第五大致癌原因和第三大致癌相关死亡原因。目前的治疗选择有限，因为已证明HCC对大多数当前治疗方式具有高度抗性。基因治疗、溶瘤病毒、放射性栓塞和几种新的生物疗法等领域正在探索新的方法。本文总结了这些最新的临床发现，并讨论了它们在未来HCC治疗中将发挥的作用。
